The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 40.00
Ask: 41.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.50%)
Open: 40.50
High: 40.50
Low: 39.60
Prev. Close: 40.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

25 Jul 2022 07:00

RNS Number : 5251T
Venture Life Group PLC
25 July 2022
 

25 July 2022

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Trading Update

Trading in line with management's expectations for the first half and confidence in full year outlook

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces a trading update for the six months ended 30 June 2022. The Group expects to release interim results in September.

Overview

The Company expects to report revenues for the six months ended 30 June 2022 of £18.9 million, a growth of 36% over the same period previous year. This is reflective of the impact of the recent acquisitions of BBI Healthcare Limited ("BBI") and Helsinn Integrative Care Portfolio ("HICP") (together the "Acquisitions") aswell as a difficult prior year comparable.

Key Highlights:

· Group revenues of £18.9 million, a growth of 36% (35% on a constant currency basis) over last year and reflecting the impact of recent acquisitions;

· The Acquisitions contributed revenues of £6.3 million (H1 2021 reported revenues £1.4 million);

· Group gross margins and adjusted EBITDA margins improved by 4ppts and 3ppts respectively over the same period in the prior year;

· Cash inflow generated from operating activities of £1.5 million (H1 2021: £0.7 million outflow);

· Net debt before finance leases reduced to £2.6 million (Dec: £3.2 million);

· Net debt after finance leases reduced to £7.2 million (Dec: £7.5 million); and

· Order book remains strong and is ahead of the same period last year as customers place increased focus on ensuring security of supply.

 

The Acquisitions delivered revenue growth of 10% and 6% respectively on a like for like basis. Outside of the Acquisitions, the revenue performance over the remainder of the business was 1% ahead of the same period last year, driven by growth from customer brands, which, given the second half weighting of international revenues is in line with management's expectations. Whilst COVID-related lockdowns in Shanghai impacted first half performance from our new Chinese partner, the restrictions are now easing and as such we continue to expect our new partner to begin to realise the potential for our products in the Chinese market. Nonetheless we remain mindful of the risk presented by China's stance on Covid.

Including the Acquisitions, and on a proforma basis, the overall revenue performance of the Group was 4% ahead of H1 2021 which, the Board believes, highlights the resilience of Venture Life's products through the cost of living crisis and the increasing importance of selfcare to consumers.

Outlook

Although we remain mindful of the changing and challenging economic backdrop, there are signs that the supply chain issues have plateaued. The team are continuing to deliver the margin protection strategy through robust cost management and by sharing cost increases with customers wherever possible. The current order book strength is enabling supplies to be purchased cost effectively and in sufficient time to produce. The first half percentage gross margin improvement demonstrates both the accretive impact of the Acquisitions plus the progress made in mitigating some of the adverse impacts faced from increased input costs. Pre-identified cost synergies from the Acquisitions have been secured as expected and support an overall improvement in adjusted EBITDA margin percentage.

The order book remains strong and is ahead of the same time last year, including the recently acquired businesses. As seen historically in the Group, revenues are weighted towards the second half of the year and these are well underpinned by the current order book strength. Based on trading performance to date and visibility over second half revenue, the Board is confident the Group is on course to deliver full year financial performance in line with market expectations.

 

Jerry Randall, CEO of Venture Life, commented: "The Group has delivered revenue growth in the first half primarily through the Acquisitions. The challenging retail environment continued in the first half, but I am delighted to see that, notwithstanding this, a number of our own brands, as well as some customer brands, have demonstrated strong revenue growth in the period. The margin improvement seen versus 2021 is particularly encouraging, and customers have been very responsive to our request to order further out than their normal lead times, enabling us to both ensure supply of raw materials and packaging in time to produce, and manage costs. The supply chain environment continues to remain challenging, but the team has done a great job in managing this in the first half and will continue to do so in the second half.

As is normal our revenues are weighted in the second half of the year, and this will be the same for 2022, supplemented also by some orders that moved into H2 as a result of supply chain timings. The unlocking of Shanghai should allow our new partner to begin to market our products there, but these are early days and we continue to monitor the situation.

The progress to date and the order book in hand mean the Board is confident the Group will deliver financial performance in 2022 in line with market expectations."

 

*Adjusted EBITDA is EBITDA before deduction of exceptional items and share based payments

 

For further information, please contact:

 

Venture Life Group PLC +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20 74963000

Jonathan Dighe (Sales)

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKQBNABKDCOB
Date   Source Headline
1st Mar 201612:07 pmRNSResult of General Meeting and Issue of Equity
18th Feb 201610:20 amRNSDirectorate Change
12th Feb 20165:38 pmRNSCircular Publication & Notice of General Meeting
12th Feb 201612:11 pmRNSResults of Placing to Partially Fund Acquisition
12th Feb 20167:00 amRNSProposed Placing and issue of Convertible Bonds
13th Jan 20167:00 amRNSProduct Launch
23rd Dec 20157:38 amRNSTrading Update
29th Sep 20157:00 amRNSInterim Results
9th Sep 20157:00 amRNSNotice of Results
9th Jul 20157:00 amRNSPre-Close Trading Statement
10th Jun 201511:41 amRNSAGM Statement
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
22nd May 20157:00 amRNSPDMR Shareholding
15th Apr 20157:00 amRNS2014 Annual Report and Dividend Timetable
25th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSSale of trademarks: manufacturing agreement signed
26th Jan 20157:00 amRNS30-year exclusive distribution deal signed
9th Dec 20147:00 amRNSBenecol Supplement Capsule Sale Malta
4th Dec 201411:54 amRNSHolding(s) in Company
28th Nov 20147:00 amRNSShare Placing
19th Nov 20147:00 amRNSAppointment of Nominated Adviser and Broker
10th Oct 20147:00 amRNSDirector's Dealings
8th Oct 20147:00 amRNSDirector Dealings
6th Oct 20147:00 amRNSDirectors' Dealings
1st Oct 20147:00 amRNSInvestor Forum
29th Sep 20147:00 amRNSInterim Results
23rd Sep 20147:00 amRNSNew distribution agreements
5th Sep 20147:00 amRNSNotice of Interim Results
6th Aug 20147:00 amRNSNew Product Development and Board Change
7th Jul 20147:00 amRNSNew distribution agreement signed
30th Jun 201412:09 pmRNSAGM Statement
30th Jun 20147:00 amRNSTotal Voting Rights
25th Jun 20147:00 amRNSNew distribution agreements signed
17th Jun 20147:00 amRNSAppointment of Non-Executive Director
13th Jun 20149:44 amRNSHolding(s) in Company
5th Jun 20147:01 amRNSIssue of new shares
5th Jun 20147:00 amRNSFinal Results
23rd Apr 20147:00 amRNSNew Distribution Agreement
28th Mar 20148:00 amRNSAdmission to AIM and Acquisition of Biokosmes Srl

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.